These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27776672)

  • 21. Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype.
    Georgiou P; Zanos P; Garcia-Carmona JA; Hourani S; Kitchen I; Laorden ML; Bailey A
    Neuropharmacology; 2016 Jun; 105():520-532. PubMed ID: 26896754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid use.
    McKetin R; Kelly E; McLaren J; Proudfoot H
    Drug Alcohol Rev; 2008 Sep; 27(5):482-9. PubMed ID: 18608459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevalence and Therapy of Crystal Methamphetamine Dependence].
    Soyka M; Koller G; Proebstl L; Kamp F; Franke A; Schmidt P; Baumgärtner G; Schacht-Jablonowsky M; Sievert A; Straif M; Hamdorf W
    Fortschr Neurol Psychiatr; 2017 Feb; 85(2):92-99. PubMed ID: 28235211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment.
    Shoptaw S; Peck J; Reback CJ; Rotheram-Fuller E
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():161-8. PubMed ID: 12825759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential benefits of quetiapine in the treatment of substance dependence disorders.
    Sattar SP; Bhatia SC; Petty F
    J Psychiatry Neurosci; 2004 Nov; 29(6):452-7. PubMed ID: 15644986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An exploratory study on association between family relationship and relapse among methamphetamine users in Compulsory Treatment System of Khon Kaen and Yasothon Provinces.
    Rodseeda P; Ratanasiri A; Kanato M; Pinitsoontorn S; Chiawiriyabunya I
    J Med Assoc Thai; 2010 Mar; 93 Suppl 3():S1-5. PubMed ID: 21302405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
    Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
    Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contingency management: an evidence-based component of methamphetamine use disorder treatments.
    Roll JM
    Addiction; 2007 Apr; 102 Suppl 1():114-20. PubMed ID: 17493060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
    Hester R; Lee N; Pennay A; Nielsen S; Ferris J
    Exp Clin Psychopharmacol; 2010 Dec; 18(6):489-97. PubMed ID: 21186923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users.
    McKetin R; Gardner J; Baker AL; Dawe S; Ali R; Voce A; Leach LS; Lubman DI
    Psychiatry Res; 2016 Apr; 238():166-171. PubMed ID: 27086229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The nature, time course and severity of methamphetamine withdrawal.
    McGregor C; Srisurapanont M; Jittiwutikarn J; Laobhripatr S; Wongtan T; White JM
    Addiction; 2005 Sep; 100(9):1320-9. PubMed ID: 16128721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes for methamphetamine users receiving outpatient counselling from the Stimulant Treatment Program in Australia.
    McKetin R; Dunlop AJ; Holland RM; Sutherland RA; Baker AL; Salmon AM; Hudson SL
    Drug Alcohol Rev; 2013 Jan; 32(1):80-7. PubMed ID: 22642414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological treatments for methamphetamine addiction: current status and future directions.
    Ballester J; Valentine G; Sofuoglu M
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapeutic agents in the treatment of methamphetamine dependence.
    Morley KC; Cornish JL; Faingold A; Wood K; Haber PS
    Expert Opin Investig Drugs; 2017 May; 26(5):563-578. PubMed ID: 28351169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning.
    Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson R;
    Am J Addict; 2010; 19(5):385-90. PubMed ID: 20716300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
    Soares E; Pereira FC
    Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of methamphetamine use disorders: an update.
    Rawson RA; Gonzales R; Brethen P
    J Subst Abuse Treat; 2002 Sep; 23(2):145-50. PubMed ID: 12220612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methamphetamine use by incarcerated women: comorbid mood and anxiety problems.
    Vik PW
    Womens Health Issues; 2007; 17(4):256-63. PubMed ID: 17544297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers.
    London ED; Simon SL; Berman SM; Mandelkern MA; Lichtman AM; Bramen J; Shinn AK; Miotto K; Learn J; Dong Y; Matochik JA; Kurian V; Newton T; Woods R; Rawson R; Ling W
    Arch Gen Psychiatry; 2004 Jan; 61(1):73-84. PubMed ID: 14706946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
    Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
    Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.